Gareth J. Morgan, MD, PhD, discusses differences in low- and high-risk multiple myeloma.
Gareth J. Morgan, MD, PhD
Advertisement
Articles by Gareth J. Morgan, MD, PhD
Gareth J. Morgan, MD, PhD, discusses optimizing treatments for patients with ultra high–risk multiple myeloma.
Gareth J. Morgan, MD, PhD, discusses the evolution of treatment options in multiple myeloma.
Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.
Gareth J. Morgan, MD, PhD, provides insight on determining treatment selection for patients with multiple myeloma.
Gareth J. Morgan, MD, PhD, discusses research examining idecabtagene vicleucel in relapsed/refractory multiple myeloma.
Gareth J. Morgan, MD, PhD, discusses the role of venetoclax in treating patients with multiple myeloma.
Gareth J. Morgan, MD, PhD, a professor in the Department of Medicine and director of Multiple Myeloma Research, NYU Langone Health’s Perlmutter Cancer Center, discusses BCMA-targeted antibody-drug conjugates (ADCs) in multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Morgan on the Differences in Low- and High-Risk Multiple MyelomaPublished: August 2nd 2021 | Updated:
Dr. Morgan on the Role of Venetoclax in Multiple MyelomaPublished: April 14th 2020 | Updated:
Dr. Morgan on Idecabtagene Vicleucel in Multiple MyelomaPublished: April 17th 2020 | Updated:
Dr. Morgan on Treatment Selection in Multiple MyelomaPublished: May 22nd 2020 | Updated:
Dr. Morgan on Optimizing Treatment in Ultra High–Risk Multiple MyelomaPublished: May 27th 2021 | Updated:
Dr. Morgan on BCMA-Targeted ADCs in Multiple MyelomaPublished: March 18th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma
5